[{"id":"40f5121b-bb06-4c08-8167-45765aada070","acronym":"KCP-8602-801","url":"https://clinicaltrials.gov/study/NCT02649790","created_at":"2021-01-17T17:34:58.356Z","updated_at":"2024-07-02T16:35:00.978Z","phase":"Phase 1/2","brief_title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","source_id_and_acronym":"NCT02649790 - KCP-8602-801","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Inqovi (decitabine/cedazuridine) • eltanexor (KPT-8602)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 277","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-24"}]